الفهرس 
D-DIMEROnly 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Background: Venous thromboembolism (VTE) is a term including deep vein thrombosis (DVT) and pulmonary embolism (PE). VTE is potentially a fatal disease because of its high morbidity and mortality in outpatients and inpatients, especially in hospitalized patients. Therefore, timely and accurate diagnosis of both is essential as delayed or missed diagnoses can result in death or longer-term complications. At the same time, the lack of subjective clinical symptoms and objective clinical signs complicates the diagnosis.
Objective: To assess the influence of oral anticoagulants on D-dimer levels in patients with VTE on days 0,14 and 30 post-anticoagulation.
Methods: This Cohort study was conducted in Ain Shams University Hospitals, on 50 patients with radiologically confirmed DVT from September 2021 till March 2022.
Results: We correlated the frequencies of D-dimer levels above cut-off value in the studied patients on different anticoagulants. For this analysis, D-dimer levels ≥ 0.50 mg/l was defined as cut-off. Positive D-dimer values were statistically significantly higher in patients on Rivaroxaban and Apixaban than in VKA users after 30 days, with p value of 0.042.
Conclusion: Our study reveals that the rate of positive D-dimer levels assessed serially during anticoagulation (at day 14 and 30 post anticoagulation) was significantly higher in patients treated with DOACs than warfarin. This may highlight the value of extended anticoagulation for patients who present with persistently elevated D-dimer levels to avoid the risk of VTE recurrence.